Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 1,551 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ulcerative Clear all

Conditions: Colitis, Ulcerative
Interventions: Spesolimab, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Hamden, Connecticut • Miami, Florida • Orlando, Florida + 10 more

Conditions: Ulcerative Colitis
Interventions: Telotristat Etiprate, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 11
States / cities: Little Rock, Arkansas • Anaheim, California • Santa Monica, California + 8 more

Conditions: Pyoderma Gangrenosum
Interventions: vilobelimab; Drug
Lead sponsor: InflaRx GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Sacramento, California • Miami, Florida • Tampa, Florida + 4 more

Conditions: Pressure Ulcer
Interventions: dHACM; Procedure
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Peripheral Artery Disease, Ischaemic Ulcer of Lower Leg Due to Atherosclerotic Disease, Chronic Limb Threatening Ischemia, Ischemic Ulcer of Foot
Interventions: AMG0001, Placebo; Biological
Lead sponsor: AnGes USA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 20
States / cities: Carlsbad, California • Downey, California • Fresno, California + 16 more

Conditions: Colitis, Ulcerative
Interventions: VTX002, Placebo; Drug
Lead sponsor: Oppilan Pharma Ltd; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 19
States / cities: Garden Grove, California • Lancaster, California • San Diego, California + 16 more

Conditions: Pressure Ulcer Not Visible
Interventions: Spatial Frequency Domain Imaging; Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Orange, California

Conditions: Diabetic Foot Ulcers
Interventions: Autologous platelet rich plasma gel, Placebo; Device
Lead sponsor: Regen Lab SA; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: McAllen, Texas

Conditions: Gastrinoma, Zollinger Ellison Syndrome
Interventions: Pantoprazole, Omeprazole; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1983 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ulcerative Colitis, Pediatric, Inflammatory Bowel Diseases, Crohn Disease
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 1 Year to 18 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 1 more

Conditions: Spinal Cord Injury
Interventions: Daily telephone calls, Weekly telephone calls; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Hines, Illinois • Cleveland, Ohio

Conditions: Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
Interventions: GORE® VIAFORT Vascular Stent; Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 24
States / cities: Stanford, California • Darien, Connecticut • New Haven, Connecticut + 20 more

Conditions: Spinal Cord Injuries, Pressure Ulcer
Interventions: Dabir Air overlay; Device
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Ulcerative Colitis (UC)
Interventions: risankizumab IV, placebo for risankizumab, risankizumab SC; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 1,558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 82
States / cities: Coronado, California • Irvine, California • La Jolla, California + 63 more

Conditions: Diabetic Foot Ulcers
Interventions: EpiCord, Standard of Care; Biological · Other
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 13
States / cities: Birmingham, Alabama • Tucson, Arizona • Carlsbad, California + 10 more

Conditions: Pyoderma Gangrenosum
Interventions: Humira; Drug
Lead sponsor: Wright State University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Ulcerative Colitis (UC)
Interventions: Selenium supplementation, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease (CD), Anal Human Papillomavirus
Interventions: Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Ulcerative Colitis
Interventions: High Protein and Low Fiber Diet, Low Protein and High Fiber Diet; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Ulcerative Colitis
Interventions: Tulisokibart, Companion Diagnostic (CDx) Testing, Placebo; Drug · Device · Other
Lead sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 29
States / cities: Mobile, Alabama • Phoenix, Arizona • Sun City, Arizona + 24 more

Conditions: Clostridium Difficile Infection, Ulcerative Colitis, Indeterminate Colitis
Interventions: Fecal Microbial Transplantation; Biological
Lead sponsor: Stony Brook University; Other
Eligibility: 7 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Ulcerative Colitis
Interventions: Brazikumab Maintenance Dose, Brazikumab Induction Dose; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 10
States / cities: Chula Vista, California • Lancaster, California • Colorado Springs, Colorado + 7 more

Conditions: Ulcerative Colitis
Interventions: High Protein, High Fiber (HPHF) Diet; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Mobility Limitation
Interventions: Lightweight wheelchair, Skin Protection Cushion; Device
Lead sponsor: University of Pittsburgh; Other
Eligibility: 60 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis

A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis

Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum

A Single Center, Prospective, Case Series of the Treatment of Pressure Ulcers and Decubitus Ulcers.

Study of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects With Peripheral Ischemic Ulcers

VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

Assessment of the Potential for Pressure Ulcer Formation

Evaluate the Safety and Efficacy of RegenKit Autologous PRP Gel for the Treatment of Diabetic Foot Ulcer

The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid

COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)

Developing a Home Telehealth Program to Manage Pressure Ulcers in SCI/D

The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study

Alternating Pressure Overlay on Weight Bearing Tissue Tolerance in People With Spinal Cord Injury

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Dehydrated Human Umbilical Cord Allograft in the Management of Diabetic Foot Ulcers

Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum

Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies

Anal Human Papillomavirus in Inflammatory Bowel Disease Study

UC Cohort - The Influence of Diet on Gut Microbiotas

A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)

Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate Colitis

Open-label Extension Study of Brazikumab in Ulcerative Colitis

Microbiome-targeted Diet Therapy in Ulcerative Colitis

Wheeled Mobility for Preventing Pressure Ulcers